The power of molecular diagnostics to direct the choice of therapies, reduce costs, and provide clinically valuable information is resulting in major market changes. The new science and new business strategies have led to strong investor interest in the field. This short course will review new and old models and describe several alternative strategies which diagnostic firms may pursue. Depending on the venture’s strengths and weaknesses, partnering or course changes may be appropriate, particularly in seeking future funding.
- Why and how diagnostics markets have changed
- Characteristics of successful ventures
- Alternate strategies for success
- What are your assets?
- How to consider your strategy
- Conventional or new markets: Which to pursue?
- Potential partners
- Your next round of funding: where and why?
This course was recently sold out at the Molecular Medicine Tri-Conference in San Francisco